These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26159701)

  • 21. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
    Montuschi P; Ciabattoni G
    J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
    Ulrik CS
    Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
    Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.
    Cohen JS; Miles MC; Donohue JF; Ohar JA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():785-97. PubMed ID: 27143870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.
    Montuschi P; Macagno F; Valente S; Fuso L
    Curr Med Chem; 2013; 20(12):1464-76. PubMed ID: 22963553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Page CP; Matera MG
    Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease.
    Yamagata E; Soutome T; Hashimoto K; Mihara K; Tohda Y
    Curr Med Res Opin; 2016 May; 32(5):967-73. PubMed ID: 26782971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
    Vogelmeier C; Banerji D
    Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
    D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
    Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
    Molimard M; D'Andrea P
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [LAMA/LABA fixed dose combination for treatment of COPD].
    Kuwahira I
    Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS; Morjaria JB
    Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
    Ulrik CS
    Ugeskr Laeger; 2013 Aug; 175(35):1946-8. PubMed ID: 23978116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.
    Matera MG; Sanduzzi A; Alfano R; Cazzola M
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):771-7. PubMed ID: 26998725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.